Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $318.00

Krystal Biotech (NASDAQ:KRYS) had its price target upped by Bank of America from $288.00 to $318.00 in a research report report published on Thursday,Benzinga reports. Bank of America currently has a buy rating on the stock.

Several other analysts also recently weighed in on the company. Citigroup lifted their target price on Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Zacks Research raised Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Chardan Capital raised their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $271.75.

Krystal Biotech Stock Down 2.6%

KRYS stock opened at $281.53 on Thursday. The stock has a market cap of $8.16 billion, a PE ratio of 42.21 and a beta of 0.46. The firm’s 50-day simple moving average is $244.11 and its 200 day simple moving average is $192.62. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Equities analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 13.70% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in KRYS. Sound Income Strategies LLC grew its position in Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the last quarter. AdvisorNet Financial Inc acquired a new position in shares of Krystal Biotech in the 3rd quarter worth $30,000. Hantz Financial Services Inc. lifted its holdings in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after purchasing an additional 179 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at $33,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.